Skip to main content

Amgen Inc(AMGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low361.70
Day High369.76
Open:364.20
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Amgen Inc

Select a category then submit the form to load news
Tipranks
Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial
Tipranks
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT), Amgen (AMGN) and Eli Lilly & Co (LLY)
Tipranks
Amgen’s Phase 3 Gout Trial Pits Subcutaneous Pegloticase Against IV Dosing
Tipranks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), ANI Pharmaceuticals (ANIP) and ALX Oncology Holdings (ALXO)
Tipranks
Analysts Are Neutral on Top Healthcare Stocks: Amgen (AMGN), Treace Medical Concepts (TMCI)
StockStory
2 Profitable Stocks with Solid Fundamentals and 1 Facing Headwinds
GDEN
Motley Fool
A Couple's Financial Manifesto, Revisited
Tipranks
Amgen Advances Maridebart Cafraglutide Toward Mid-Stage Obesity and Liver Fat Trial
Tipranks
Amgen Fine-Tunes Evolocumab: New Bioavailability Study Signals Long-Term Cholesterol Franchise Focus
Zacks Investment Research
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?
StockStory
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
CTOS
Tipranks
Amgen Prices $4 Billion Senior Unsecured Notes Offering
StockStory
1 Momentum Stock to Research Further and 2 We Avoid
AMGN
StockStory
1 Large-Cap Stock Worth Your Attention and 2 We Avoid
MDLZ
Zacks Investment Research
AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook
AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook
StockStory
The 5 Most Interesting Analyst Questions From Amgen’s Q4 Earnings Call
AMGN
Zacks Investment Research
J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss
J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss
Tipranks
Amgen (AMGN) Receives a Buy from Argus Research
Tipranks
Amgen Advances Xaluritamig Into Early-Stage Trial for Hard-to-Treat Ewing Sarcoma
Tipranks
Amgen’s IMLYGIC Safety Study in Melanoma Reaches Completion: What Investors Should Watch
Tipranks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Johnson & Johnson (JNJ)
Tipranks
Cantor Fitzgerald Sticks to Its Hold Rating for Amgen (AMGN)
Tipranks
Amgen Earnings Call: Broad Growth Amid Manageable Risks
Tipranks
Amgen’s FORTITUDE-301 Cancer Trial Completion: What Investors Should Watch in Bemarituzumab’s Next Act
Zacks Investment Research
Zacks Investment Ideas feature highlights: Amgen, Apple and Microsoft
Zacks Investment Ideas feature highlights: Amgen, Apple and Microsoft
Motley Fool
These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys?
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Caribou Biosciences (CRBU) and Boston Scientific (BSX)
Tipranks
Scotiabank Keeps Their Buy Rating on Amgen (AMGN)
Tipranks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Pfizer (PFE) and Merck & Company (MRK)
Tipranks
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO), LENZ Therapeutics (LENZ) and Amgen (AMGN)
Zacks Investment Research
Stock Market News for Feb 5, 2026
Stock Market News for Feb 5, 2026
Tipranks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and BeOne Medicines (ONC)

Profile

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.